Search Within

Genitourinary Oncology Service

Formats
  1. Journal Article (2795)
  2. Meeting Abstract (2524)
  3. Review (119)
  4. Book Section (83)
  5. Editorial (57)
  6. Correspondence (34)
  7. Conference Paper (29)
  8. Guidelines (25)
  9. Research Letter (18)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Solid Tumor Oncology Division (5692)
  2. Department of Medicine (5682)
  3. GSK Faculty (1658)
  4. Human Oncology and Pathogenesis Program (1157)
  5. Department of Pathology and Laboratory Medicine (1129)
  6. Surgery (1021)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. David Solit (785)
  4. Dean Bajorin (664)
  5. Michael Morris (587)
  6. Jonathan Rosenberg (525)

More People

Years
  1. 2025 (200)
  2. 2024 (294)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1713)
  2. Annals of Oncology (304)
  3. Clinical Cancer Research (283)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (123)

More Publications

Publishers
  1. American Society of Clinical Oncology (1780)
  2. American Association for Cancer Research (689)
  3. Oxford University Press (414)
  4. Elsevier Science, Inc. (396)
  5. Elsevier Inc. (380)
  6. Nature Publishing Group (302)

More Publishers

Results (5692)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Peripheral-blood gene expression profiling in bladder cancer (BC) patients (pts)
    Meeting Abstract

    Apolo, A. B.; Osman, I.; Shen, R.; Olshen, A. B.; Bajorin, D. F.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Outcome prediction in adult male germ cell tumor patients through expression profiling
    Meeting Abstract

    Korkola, J.; Houldsworth, J.; Feldman, D. R.; Olshen, A. B.; Qin, L.; Patil, S.; Reuter, V. E.; Bosl, G. J.; Chaganti, R. S.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Trends in Memorial Sloan-Kettering Cancer Center risk group distribution according to treatment year for patients with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Patil, S.; Ishill, N. M.; Deluca, J.; Motzer, R. J.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • A phase I study of oral panobinostat (LBH589) alone and in combination with docetaxel (Doc) and prednisone in castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Rathkopf, D. E.; Wong, B. Y.; Ross, R. W.; George, D. J.; Picus, J.; Tanaka, E.; Chen, Y.; Atadja, P.; Yang, W.; Culver, K. W.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma
    Meeting Abstract

    Feldman, D. R.; Ginsberg, M. S.; Baum, M.; Flombaum, C.; Hassoun, H.; Velasco, S.; Fischer, P.; Ishill, N. M.; Ronnen, E. A.; Motzer, R. J.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Phase I study of docetaxel (Tax) and (153)Sm repetitively administered for castrate metastatic prostate cancer (CMPC)
    Meeting Abstract

    Morris, M. J.; Pandit-Taskar, N.; Stephenson, R. D.; Hong, C.; Slovin, S. F.; Solit, D.; Rathkopf, D. E.; Carrasquillo, J. A.; Larson, S. M.; Scher, H. I.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Beer, T. M.; Slovin, S. F.; Higano, C. S.; Tejwani, S.; Dorff, T. B.; Stankevich, E.; Lowy, I.; Prostate Cancer Clinical Trials Consortium
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Hypoxia-inducible factor (HIF) 1α and 2α levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC)
    Meeting Abstract

    Patel, P. H.; Chadalavada, R. S.; Ishill, N. M.; Patil, S.; Reuter, V. E.; Motzer, R. J.; Chaganti, R. S.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Figlin, R. A.; Hutson, T. E.; Tomczak, P.; Michaelson, M. D.; Bukowski, R. M.; Negrier, S.; Huang, X.; Kim, S. T.; Chen, I.; Motzer, R. J.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Evaluation of soluble B7x as a serum marker in patients with clear cell renal cell carcinoma
    Meeting Abstract

    Thompson, R. H.; Zang, X.; Lohse, C. M.; Leibovich, B. C.; Slovin, S. F.; Reuter, V. E.; Blute, M. L.; Russo, P.; Kwon, E. D.; Allison, J. P.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save